Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human RPS6KB2 Antibodies:
anti-Rat (Rattus) RPS6KB2 Antibodies:
anti-Mouse (Murine) RPS6KB2 Antibodies:
Go to our pre-filtered search.
Human Polyclonal RPS6KB2 Primary Antibody for IP, WB - ABIN151089
Nardella, Lunardi, Fedele, Clohessy, Alimonti, Kozma, Thomas, Loda, Pandolfi: Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis. in Cancer research 2011
Show all 2 Pubmed References
Human Polyclonal RPS6KB2 Primary Antibody for WB - ABIN392546
Strausberg, Feingold, Grouse, Derge, Klausner, Collins, Wagner, Shenmen, Schuler, Altschul, Zeeberg, Buetow, Schaefer, Bhat, Hopkins, Jordan, Moore, Max, Wang, Hsieh, Diatchenko, Marusina, Farmer et al.: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. ... in Proceedings of the National Academy of Sciences of the United States of America 2002
Show all 6 Pubmed References
Human Polyclonal RPS6KB2 Primary Antibody for IF, WB - ABIN948425
Warner, Bridge, Hewitson, Hodgkinson, Heyam, Massa, Haslam, Chatzifrangkeskou, Evans, Plevin, Sharp, Lagos: S6K2-mediated regulation of TRBP as a determinant of miRNA expression in human primary lymphatic endothelial cells. in Nucleic acids research 2016
Human Polyclonal RPS6KB2 Primary Antibody for IP - ABIN151088
Liu, Mao, LaFortune, Alonso, Gallick, Fueyo, Yung: Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade. in Cancer research 2007
p54 (show DDX6 Antibodies)-S6K2 interactome is predominant to the nucleus, whereas p70-S6K1 (show RPS6KB1 Antibodies) is predominant to cytosol.
Overexpression of catalytically-active Akt (show AKT1 Antibodies) or knockdown of glycogen synthase kinase-3 (GSK3)-beta (show GSK3b Antibodies), a substrate for Akt (show AKT1 Antibodies), had little effect on Mcl-1 (show MCL1 Antibodies) downregulation caused by S6K2 deficiency
We propose that the S6K2/TRBP (show TARBP2 Antibodies) node controls miRNA biogenesis in HDLECs and provides a molecular link between the mTOR (show FRAP1 Antibodies) pathway and the miRNA biogenesis machinery.
discovered that ERBB4 (show ERBB4 Antibodies) and S6K2 were the direct targets of miR (show MLXIP Antibodies)-193a-3p and that PIK3R3 and mTOR (show FRAP1 Antibodies) were the direct targets of miR (show MLXIP Antibodies)-193a-5p in non-small-cell lung cancer
Degradation of Tiam1 (show TIAM1 Antibodies) by casein kinase 1 (show CSNK1A1 Antibodies) and the SCFbetaTrCP ubiquitin ligase controls the duration of mTOR (show FRAP1 Antibodies)-S6K (show RPS6KB1 Antibodies) signaling.
The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer.
The p85 S6K1 (show RPS6KB1 Antibodies) promotes H2O2-induced cell death via a rapamycin-insensitive mechanism.
S6K2 amplification was frequently observed in gastric cancer and was related to a poor prognosis
S6K1 and S6K2 gene amplification was associated with a worse prognosis.
S6K2 expression dictates tissue-specific requirement for S6K1 (show RPS6KB1 Antibodies) in mediating aberrant mTORC1 signaling and tumorigenesis
S6K2 loss reduces Th17 skewing and increases regulatory T cell differentiation.
the p70S6K (show RPS6KB1 Antibodies) isoforms have unique and redundant functions in mediating fibrogenic processes, including proliferation, migration.
S6K2 regulates hepatic energy homeostasis by repressing PPARalpha (show PPARA Antibodies) activity.
metabolic functions of S6K (show RPS6KB1 Antibodies) in vivo play a key role as a molecular interface connecting dietary lipids to the endogenous control of energy metabolism.
Data show that the absence of ribosomal protein S6 (show RPS6 Antibodies) kinases 1 and 2 (S6K1 (show RPS6KB1 Antibodies) and S6K2) profoundly impairs animal viability but does not seem to affect the proliferative responses of cells derived from the distinct S6K (show RPS6KB1 Antibodies) genotypes.
S6K2 is activated by IL-3 (show IL-3 Antibodies) in the IL-3 (show IL-3 Antibodies)-dependent Ba/F3 cell line and this is mediated by mTOR (show FRAP1 Antibodies) and its upstream activator PI-3K but not by MAPK (show MAPK1 Antibodies) signal pathways.
parallel increase in p70S6K (show RPS6KB1 Antibodies) activation and tau phosphorylation could be demonstrated by treating wild-type N2a cells with Abeta25-35
mGluR (show GRM8 Antibodies)-LTD is associated with PI3K-, mTOR (show FRAP1 Antibodies)-, and ERK (show EPHB2 Antibodies)-dependent alterations in the phosphorylation of S6 and S6K (show RPS6KB1 Antibodies).
This gene encodes a member of the RSK (ribosomal S6 kinase) family of serine/threonine kinases. This kinase contains 2 nonidentical kinase catalytic domains and phosphorylates the S6 ribosomal protein and eucaryotic translation initiation factor 4B (eIF4B). Phosphorylation of S6 leads to an increase in protein synthesis and cell proliferation.
70 kDa ribosomal protein S6 kinase 2
, S6 kinase-related kinase
, p70 S6 kinase beta
, p70 S6K-beta
, p70 S6KB
, p70 ribosomal S6 kinase beta
, p70-S6K 2
, ribosomal protein S6 kinase beta-2
, serine/threonine-protein kinase 14 beta
, serine/threonine-protein kinase 14B
, ribosomal protein S6 kinase, 70kDa, polypeptide 2
, S6 kinase 2
, ribosomal protein S6 kinase, 70kD, polypeptide 2